The effect of desacetyluvaricin on the expression of tlr4 and p53 protein in hepg 2.2.15

Hepatitis Monthly

Volumn 11, Issue 5, 2011, Pages 364-367

  He, Hai Bin ^a   Wu, Xian Lin ^b   Yu, Bin ^b   Liu, Kang Li ^b   Zhou, Guang Xiong ^c   Qian, Guo Qiang ^b   da Ju, Hong ^d   Chen, Xiao Yin ^b  

^a Department of Gastroenterology   (China)

^b MEDICAL COLLEGE OF JINAN UNIVERSITY   (China)

^c JINAN UNIVERSITY   (China)

^d INSTITUTE OF CHINESE MATERIA MEDICA   (China)

Author keywords

Desacetyluvaricin tlr4 receptor p53 tumor suppressor protein flow cytometry hepatocellular carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DEACETYLUVARICIN; PROTEIN P53; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG;

ARTICLE; CELL STRAIN HEPG2; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; FLOW CYTOMETRY; LIVER CELL CARCINOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION;

EID: 79957641731     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Tempesta MS, Kriek GR, Bates RB. Uvaricin, a new antitumor agent from Uvaria accuminata (Annonaceae). J Org Chem. 1982;47(16):3145-8.
2. Liu HX, Huang GR, Zhang HM, Wu JR, Yao ZJ. Annonaceous aceto-genin mimics bearing a terminal lactam and their cytotoxicity against cancer cells. Bioorg Med Chem Lett. 2007;17(12):3426-30.
3. Chiu HF, Chih TT, Hsian YM, Tseng CH, Wu MJ, Wu YC. Bullatacin, a potent antitumor Annonaceous acetogenin, induces apoptosis through a reduction of intracellular cAMP and cGMP levels in human hepatoma 2.2.15 cells. Biochem Pharmacol. 2003;65(3):319-27.
4. Kuwabara K, Takada M, Iwata J, Tatsumoto K, Sakamoto K, Iwa-mura H, et al. Design syntheses and mitochondrial complex I inhibitory activity of novel acetogenin mimics. Eur J Biochem. 2000;267(9):2538-46.
5. Xu ZF, Wei XY, Xie HH, Yang RZ. [Inhibition of oxygen consumption by annonaceous acetogenins in liver cell respiration and their structure-activity relationship]. Yao Xue Xue Bao. 2002;37(10):818-20.
6. Xiao-yin C, Guang-xiong Z, Chang-lin Z, Fang XIA, Hui-jun MAO, Zhen-you J, et al. Effect of a Monomer Desacetyluvari-cin of Annonaceous Acetogenin on Growth and Apoptosis of Hepatoma Carcinoma Cell Strain. J Sun Yat-Sen Univ Med Sci. 2007;3(28):254-7.
7. Zhang ZR, Zhong LF. Cultural Cytology and Technique for Cell Culture. Sci Technol, Shanghai. 2004:47-51.
8. Morkve O, Laerum OD. Flow cytometric measurement of p53 protein expression and DNA content in parafn-embedded tissue from bronchial carcinomas. Cytometry. 1991;12(5):438-44.
9. Kastan MB, Radin AI, Kuerbitz SJ, Onyekwere O, Wolkow CA, Civin CI, et al. Levels of p53 protein increase with maturation in human hematopoietic cells. Cancer Res. 1991;51(16):4279-86.
10. Wang J, Cao L, He M. [Flow cytometric 3-color analysis of circulating activated platelets and its clinical signifcance in ischemic cerebrovascular diseases]. Zhonghua Yi Xue Za Zhi. 2000;80(7):499-502.
11. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol. 2004;5(10):987-95.
12. Bauer AK, Dixon D, DeGraf LM, Cho HY, Walker CR, Malkinson AM, et al. Toll-like receptor 4 in butylated hydroxytoluene-in-duced mouse pulmonary infammation and tumorigenesis. J Natl Cancer Inst. 2005;97(23):1778-81.
13. Lin Y, Nomura T, Yamashita T, Dorjsuren D, Tang H, Murakami S. The transactivation and p53-interacting functions of hepatitis B virus X protein are mutually interfering but distinct. Cancer Res. 1997;57(22):5137-42.
14. Lee SG, Rho HM. Transcriptional repression of the human p53 gene by hepatitis B viral X protein. Oncogene. 2000;19(3):468-71.
15. Chen X, Ko LJ, Jayaraman L, Prives C. p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev. 1996;10(19):2438-51.